Skyhawk Therapeutics is a Cambridge, Mass.-based drug development company developing small-molecule therapies that correct RNA mutations via its STAR* platform. The company's STAR* (Small molecule Therapies for Alternative splicing in RNA) platform is designed to discover and develop small molecules that modulate alternative splicing in RNA. It is pursuing indications in neurology, oncology and immunology and expects its first oncology drug to enter the clinic by the end of 2019. Led by co-founder and CEO Bill Haney, Skyhawk focuses on discovering, developing and commercializing therapies using its platform. Recently the company closed a $40M all-common-stock equity round alongside a $60M strategic collaboration, bringing over $100M in new capital to fund development. Skyhawk Therapeutics develops small molecules that correct RNA expression, with an initial focus on therapies that address exon skipping. The company leverages proprietary technology to rationally design small molecules that bind specific pockets on RNA using sequence and structural specificity at defined moments in the splicing process. Its initial programs target a set of 50+ diseases driven by exon skipping, including broad-based neurological conditions and previously “undruggable” oncogenes in cancer. Skyhawk intends to use the seed financing to advance its portfolio of specific and selective small molecules against these targets. The company is based in Waltham, Massachusetts. Founders and founding board members include William Haney (co-founder and executive chairman), Kathleen McCarthy (co-founder and CEO), Kevin Koch, Andrew Boyd and Andrew Bedford.

Total raised

$48M

Funding rounds

2

Latest round

Equity

Latest activity

Jun 2018